These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 29760145

  • 1. In Vitro Activity of Imipenem-Relebactam and Ceftolozane-Tazobactam against Resistant Gram-Negative Bacilli.
    Schmidt-Malan SM, Mishra AJ, Mushtaq A, Brinkman CL, Patel R.
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29760145
    [Abstract] [Full Text] [Related]

  • 2. Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.
    Sader HS, Castanheira M, Duncan LR, Mendes RE.
    Int J Infect Dis; 2021 Dec; 113():279-281. PubMed ID: 34670144
    [Abstract] [Full Text] [Related]

  • 3. Activity of imipenem-relebactam and ceftolozane-tazobactam against carbapenem-resistant Pseudomonas aeruginosa and KPC-producing Enterobacterales.
    Bail L, Ito CAS, Arend LNVS, Nogueira KDS, Tuon FF.
    Diagn Microbiol Infect Dis; 2022 Jan; 102(1):115568. PubMed ID: 34749296
    [No Abstract] [Full Text] [Related]

  • 4. In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial Resistance Trends, United States 2015-2017.
    Karlowsky JA, Lob SH, Raddatz J, DePestel DD, Young K, Motyl MR, Sahm DF.
    Clin Infect Dis; 2021 Jun 15; 72(12):2112-2120. PubMed ID: 32246147
    [Abstract] [Full Text] [Related]

  • 5. Activity of imipenem/relebactam and comparators against KPC-producing Klebsiella pneumoniae and imipenem-resistant Pseudomonas aeruginosa.
    Delgado-Valverde M, Portillo-Calderón I, Alcalde-Rico M, Conejo MC, Hidalgo C, Del Toro Esperón C, Pascual Á.
    Eur J Clin Microbiol Infect Dis; 2024 Mar 15; 43(3):445-457. PubMed ID: 38157139
    [Abstract] [Full Text] [Related]

  • 6. In-vitro activity of imipenem/relebactam and key β-lactam agents against Gram-negative bacilli isolated from lower respiratory tract infection samples of intensive care unit patients - SMART Surveillance United States 2015-2017.
    Karlowsky JA, Lob SH, Kazmierczak KM, Young K, Motyl MR, Sahm DF.
    Int J Antimicrob Agents; 2020 Jan 15; 55(1):105841. PubMed ID: 31704217
    [Abstract] [Full Text] [Related]

  • 7. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, Lagacé-Wiens PRS, Walkty A, Denisuik A, Golden A, Gin AS, Hoban DJ, Lynch JP, Karlowsky JA.
    Drugs; 2018 Jan 15; 78(1):65-98. PubMed ID: 29230684
    [Abstract] [Full Text] [Related]

  • 8. Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa.
    Lasarte-Monterrubio C, Fraile-Ribot PA, Vázquez-Ucha JC, Cabot G, Guijarro-Sánchez P, Alonso-García I, Rumbo-Feal S, Galán-Sánchez F, Beceiro A, Arca-Suárez J, Oliver A, Bou G.
    J Antimicrob Chemother; 2022 Sep 30; 77(10):2809-2815. PubMed ID: 35904000
    [Abstract] [Full Text] [Related]

  • 9. Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Greece and Italy-SMART 2017-2021.
    Karlowsky JA, Lob SH, Hawser SP, Kothari N, Siddiqui F, Alekseeva I, DeRyke CA, Young K, Motyl MR, Sahm DF.
    Eur J Clin Microbiol Infect Dis; 2024 Jul 30; 43(7):1343-1348. PubMed ID: 38775873
    [Abstract] [Full Text] [Related]

  • 10. In Vitro Activity of Cefepime-Enmetazobactam against Gram-Negative Isolates Collected from U.S. and European Hospitals during 2014-2015.
    Morrissey I, Magnet S, Hawser S, Shapiro S, Knechtle P.
    Antimicrob Agents Chemother; 2019 Jul 30; 63(7):. PubMed ID: 30988152
    [Abstract] [Full Text] [Related]

  • 11. Imipenem/relebactam activity compared to other antimicrobials against non-MBL-producing carbapenem-resistant Enterobacteriaceae from an academic medical center.
    Kulengowski B, Burgess DS.
    Pathog Dis; 2019 Jun 01; 77(4):. PubMed ID: 31365075
    [Abstract] [Full Text] [Related]

  • 12. In Vitro Activity of WCK 5222 (Cefepime-Zidebactam) against Worldwide Collected Gram-Negative Bacilli Not Susceptible to Carbapenems.
    Karlowsky JA, Hackel MA, Bouchillon SK, Sahm DF.
    Antimicrob Agents Chemother; 2020 Nov 17; 64(12):. PubMed ID: 32928739
    [Abstract] [Full Text] [Related]

  • 13. Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia.
    Henderson A, Tan E, McCarthy KL, Paterson DL.
    Pathology; 2018 Dec 17; 50(7):748-752. PubMed ID: 30392710
    [Abstract] [Full Text] [Related]

  • 14. In vitro activity of cefiderocol against carbapenemase-producing and meropenem-non-susceptible Gram-negative bacteria collected in the Japan Antimicrobial Resistant Bacterial Surveillance.
    Kayama S, Kawakami S, Kondo K, Kitamura N, Yu L, Hayashi W, Yahara K, Sugawara Y, Sugai M.
    J Glob Antimicrob Resist; 2024 Sep 17; 38():12-20. PubMed ID: 38789082
    [Abstract] [Full Text] [Related]

  • 15. In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme.
    Karlowsky JA, Lob SH, Kazmierczak KM, Hawser SP, Magnet S, Young K, Motyl MR, Sahm DF.
    J Antimicrob Chemother; 2018 Jul 01; 73(7):1872-1879. PubMed ID: 29659861
    [Abstract] [Full Text] [Related]

  • 16. In vitro activity of imipenem-relebactam against resistant phenotypes of Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples - SMART Surveillance Europe 2015-2017.
    Lob SH, Karlowsky JA, Young K, Motyl MR, Hawser S, Kothari ND, Sahm DF.
    J Med Microbiol; 2020 Feb 01; 69(2):207-217. PubMed ID: 31976856
    [Abstract] [Full Text] [Related]

  • 17. Activity of imipenem/relebactam against carbapenemase-producing Enterobacteriaceae with high colistin resistance.
    Carpenter J, Neidig N, Campbell A, Thornsberry T, Truex T, Fortney T, Zhang Y, Bush K.
    J Antimicrob Chemother; 2019 Nov 01; 74(11):3260-3263. PubMed ID: 31430370
    [Abstract] [Full Text] [Related]

  • 18. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
    Alatoom A, Elsayed H, Lawlor K, AbdelWareth L, El-Lababidi R, Cardona L, Mooty M, Bonilla MF, Nusair A, Mirza I.
    Int J Infect Dis; 2017 Sep 01; 62():39-43. PubMed ID: 28610832
    [Abstract] [Full Text] [Related]

  • 19. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012).
    Farrell DJ, Sader HS, Flamm RK, Jones RN.
    Int J Antimicrob Agents; 2014 Jun 01; 43(6):533-9. PubMed ID: 24856078
    [Abstract] [Full Text] [Related]

  • 20. Activity of ceftolozane-tazobactam and comparators against gram-negative bacilli: Results from the study for monitoring antimicrobial resistance trends (SMART - Brazil; 2016-2017).
    Beirão EM, Rodrigues SDS, Andrade TK, Serra FB, Paula MDN, Polis TJB, Gales AC.
    Braz J Infect Dis; 2020 Jun 01; 24(4):310-321. PubMed ID: 32663440
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.